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Vancomycin-induced acute generalized
exanthematous pustulosis (AGEP)
masquerading septic shock—an unusual
presentation of a rare disease
Sagger Mawri1*, Tarun Jain1, Jainil Shah1, Gina Hurst2 and Jennifer Swiderek3

Abstract
Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous adverse reaction characterized by acute
sterile pustular eruptions, mostly induced by medications. Antibiotics are the most commonly implicated drugs;
however, there have only been two previous reports of vancomycin-induced AGEP in the literature. In this case, we
present the clinical course of a 56-year-old man who was admitted to the intensive care unit with an unusually
severe form of AGEP mimicking septic shock, which developed after the recent use of vancomycin. Despite
cessation of the offending agent, our patient continued to clinically decline with development of worsening skin
eruptions and hemodynamic instability necessitating vasopressor support. The patient promptly responded to
systemic steroid therapy with complete resolution of AGEP. In addition to highlighting the implication of vancomycin
in AGEP, we herein discuss the clinical presentation, diagnosis, and management of AGEP, particularly in severe cases
admitted to the intensive care unit.
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Background
Acute generalized exanthematous pustulosis (AGEP) is a
rare disorder characterized by an acute-onset severe cutaneous reaction manifesting as several non-follicular pustules on a diffuse erythematous edema [1, 2]. It is usually a
drug-related reaction, with antibiotics most commonly implicated [2]. It is typically a self-limited condition that resolves spontaneously with cessation of the offending
agent. While it typically has systemic features such as fever
and leukocytosis, it rarely causes multi-organ involvement
[3]. Herein, we describe a unique case of vancomycininduced AGEP in a middle-aged male presenting with
distributive shock and multi-org.
Case presentation
A 56-year-old man with newly diagnosed glioblastoma
multiforme underwent craniotomy and tumor resection
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followed by external beam radiation and concurrent
chemotherapy with temozolomide. His post-operative
course was complicated by an epidural abscess, which
was initially drained. Fluid cultures revealed methicillinresistant streptococcus epidermitis (MRSE). The patient
subsequently underwent resection of the abscess followed
by cranioplasty with placement of a vancomycinimpregnated titanium mesh to repair the skull defect. He
was discharged home on a course of steroid therapy for
vasogenic edema noted on post-operative brain MRI as
well as an 8-week course of intravenous vancomycin administered via a peripherally inserted central catheter. His
steroid taper was dexamethasone 4 mg po twice a day for
3 days, then 2 mg twice a day for 3 days, then 2 mg once a
day for 3 days, and 1 mg once a day for 3 days.
The patient tolerated the antibiotic infusion well. Two
weeks later, having completed his dexamethasone taper
2 days prior, he presented to the emergency department
complaining of a diffuse red, itchy rash. He also reported
experiencing fevers reaching 38 °C and chills over the
past day. He denied any face or tongue swelling, nausea,
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vomiting, abdominal pain, or diarrhea. He reported no
prior skin rashes or allergic reactions and no new medications or other antibiotics. He was not on any other
medications except the IV antibiotic infusion.
On presentation, the patient was febrile at 38.4 °C,
tachycardic at 130/min, tachypneic at 32/min, hypotensive
at 88/55 mmHg, and saturating 96 % on room air. Physical
examination revealed numerous small studded pustules on
an erythematous background on the forehead, frontal
scalp, cheeks, trunk, upper and lower extremities, and axilla, with numerous erythematous macules and papules
coalescing into plaques noted on the back, trunk, and extremities (Fig. 1). There was no evidence of mucous membrane involvement, lymphadenopathy, or organomegaly.
There was no neck stiffness, changes in speech, numbness,
or weakness. Initial laboratory studies revealed a normal
white blood cell count (9200/μL) with a left shift (22 %
bands) and without eosinophilia, an elevated lactate level
(3.2 mmol/L), normal TSH, and minimally elevated Creactive protein and erythrocyte sedimentation rate. His
serum creatinine was 1.2 mg/dL with GFR of 89 mL/min.
His liver function tests were mildly elevated (AST 56 IU/L;
ALT 50 IU/L).
The patient was aggressively resuscitated with multiple
intravenous crystalloid fluid boluses. Vancomycin was
stopped and intravenous linezolid was started. Chest
radiograph was normal. Brain MRI did not show evidence of leptomeningeal enhancement or signs of recurrent infection. Abdominal ultrasound was unremarkable.
The patient was admitted to the infectious disease ward
to undergo further work-up. Dermatology was consulted
and skin biopsies were obtained. He was started on topical steroids for the skin rash, which was suspected to be
acute generalized exanthematous pustulosis. However,
the patient continued to have fevers, and he remained

Fig. 1 Day 3 of hospital admission, before initiation of systemic
steroid therapy. Numerous small studded pustules on an erythematous
background with numerous erythematous macules and papules
coalescing into plaques are noted in various body parts
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tachycardic, tachypneic, and hypotensive despite multiple intravenous fluid boluses. His urine output became
diminished and his mental status became depressed. His
antibiotic coverage was broadened to include intravenous cefepime and metronidazole in addition to linezolid. He was transferred overnight to the medical
intensive care unit for escalation of care and suspected septic shock.
While in the intensive care unit, the patient was continued on empiric broad-spectrum antibiotic coverage
and given additional intravenous fluid boluses. He continued to have tachycardia, tachypnea, increased work of
breathing, and fevers reaching 39 °C. The skin examination worsened, with more diffuse skin involvement and
development of edema of the face. Laboratory investigation revealed bandemia (28 %). He developed increasing
somnolence, reduced urine output, signs of volume overload with elevated central venous pressure (14 mmHg),
and increasing oxygen requirements. Vasopressors were
started for hypotension. The infectious work-up was negative to date, including multiple sets of negative blood cultures. Histopathological examination of the skin punch
biopsy revealed sub-corneal and intraepidermal pustules,
widespread spongiosis, and neutrophil infiltration around
the vessels in the papillary dermis—findings consistent
with acute generalized exanthematous pustulosis (Fig. 2).
In light of the patient’s worsening clinical status and apparent lack of response to topical steroids, he was started
on high-dose steroids with Solu-Medrol 80 mg IV daily
per recommendations from the dermatology consult team.
The patient’s weight was 79.5 kg; thus, steroid dosing was
determined using 1 mg/kg dosing calculation, which has

Fig. 2 Histopathology of skin biopsy revealing spongiotic epidermis
with focal parakeratosis, exocytosis, and spongiotic vesicles, along
with papillary dermal edema, superficial dermal perivascular
inflammatory infiltrate, and mixed dermal interstitial inflammation
with eosinophils (H&E, ×10). The arrow points to the "papillary dermal
edema and superficial dermal perivascular inflammatory infiltrate"
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been shown to be an effective starting dose for severe
AGEP and similar dermatologic conditions.
The patient responded remarkably well to the systemic
steroids. He had rapid clinical improvement and within
hours became afebrile, was weaned off of the vasopressors, and had complete resolution of his tachycardia and
tachypnea. His mental status improved, urine output increased, and respiratory status normalized. Within 24 h,
the skin rash had regressed significantly (Fig. 3). The
antibiotics were discontinued, except for linezolid. Intravenous Solu-Medrol was transitioned to prednisone
80 mg oral daily. The patient was discharged home in
stable condition on a prednisone taper, planned to be titrated down by 10 mg weekly. He was also discharged
on linezolid 600 mg oral twice a day to complete his initial antibiotic course. Six months later, the patient has
completed his antibiotic and steroid treatment courses
and continues to do well. The patch test for vancomycin
was deemed unnecessary by the dermatology consult
team because the patient was not on any home medications aside from steroids and vancomycin; thus, the only
obvious culprit was vancomycin. In vitro testing such as
macrophage migration inhibition factor (MIF) test or
mast cell degranulation (MCD) test were not performed,
as these are unavailable at our institution.

Discussion

AGEP is a rare disorder characterized by the acute development of sterile, non-follicular pinhead-sized pustular eruptions overlying an edematous erythema [1, 2].
Characteristically, the skin reaction arises rapidly within
a few hours and tends to resolve quickly within several
days after cessation of the offending agent or may resolve spontaneously. The rash mostly begins in the
intertriginous areas or in the face then spreads diffusely and is often described as a burning or itching

Fig. 3 Day 4 of hospital admission, after initiation of systemic steroid
therapy. Significant regression of skin eruptions noted
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sensation. In about 20 % of cases, mucous membranes are involved but tend to be mild and usually
limited to the oral cavity [1].
The incidence of AGEP has been approximated at 1 to
5 cases per million annually [4]. More than 90 % AGEP
cases are related to drugs, with viruses comprising the
next most common trigger. The most commonly implicated drugs are antibiotics, including pristinamycin,
ampicillin, amoxicillin, macrolides, and quinolones.
Other drugs include calcium channel blockers and antifungal agents [2]. Although sulfa drugs can cause
many skin reactions, they are usually not implicated
in AGEP [5].
AGEP commonly presents with high fevers and neutrophilia concurrently occurring with the skin eruptions,
thus often misinterpreted as an acute infectious disease.
It tends to occur suddenly within 1 to 2 days of exposure
to the offending agent and is generally self-limited when
the causative agent is eliminated. The skin pustules typically begin on the face and within hours spread to the
trunk and limbs and tend to coalesce. Multi-organ involvement is rare and highly atypical of AGEP [3, 6].
Histological evaluation of the involved skin shows
spongiform subcorneal and intraepidermal pustules,
papillary dermal edema, and neutrophilic infiltration
around papillary dermal blood vessels [1].
Important differential diagnoses for AGEP include
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN). The systemic features of AGEP usually
manifest early, whereas SJS/TEN tends to have a slower
manifestation, usually after 3 weeks, and characteristically presents with blisters and severe mucus membrane
involvement. Furthermore, the drugs implicated in SJS/
TEN are usually different, such as antiepileptic agents or
allopurinol [7].
A useful algorithm for the diagnosis of AGEP was
proposed by Sidoroff et al. [1]. The validation score
combines clinical and histological features, such as the
type and distribution of the skin rash, presence of
leukocytosis, histological findings, and the timing of the
skin reaction. A score of 8 to 12 is definitive for the
diagnosis of AGEP. Applying the AGEP validation score
resulted in a score of 11 in our patient, confirming the
diagnosis.
Typically self-limiting in nature, AGEP tends to resolve spontaneously with cessation of the offending
agent and no further measures are usually required. The
use of steroids is not routinely required and if indicated,
usually topical steroids suffice in providing clinical improvement [6]. Systemic steroids have been used on rare
occasions when AGEP presents atypically with severe
systemic involvement [8–10].
Our case has several unique features. First, the onset
of AGEP was delayed for a couple of weeks after
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initiation of the offending antibiotic, and this was most
likely because the patient was on concurrent steroid
therapy for his vasogenic cerebral edema. Immediately
following completion of the steroid therapy, and hence
loss of its anti-inflammatory effects, AGEP was abruptly
unmasked.
Second, in contrast to most reported cases of AGEP,
our case demonstrates an atypical presentation with severe systemic involvement and multi-organ failure mimicking septic shock. The clinical presentation continued
to deteriorate despite cessation of the offending antibiotic. Because the patient was only on a brief (12 days)
and tapered-down course of steroid therapy, it was not
felt that his hemodynamic instability was secondary to
adrenal insufficiency, and thus, this was not worked up
with laboratory testing.
Third, the presence of antibiotic-impregnated intracranial mesh added another layer of complexity to our case,
as it was not evident what role this played in our patient’s
clinical picture. While there is scarce data in current
literature on this particular matter, it has been reported
that systemic absorption and side effects in antibioticimpregnated orthopedic implants are usually minimal
[11]. However, given the continued clinical decline of our
patient after cessation of the systemic antibiotic, one may
speculate about the potential contribution of antibiotic release from the intracranial mesh.
Fourth, the role of systemic steroids in the management of AGEP is rarely indicated and topical steroids
usually suffice if the disorder does not resolve with cessation of the offending agent [3]. However, as our case
illustrates, despite the use of topical steroids, the patient’s skin eruptions progressed rapidly coinciding with
rapid clinical decline, hemodynamic instability, and
multi-organ involvement necessitating vasopressors. Administration of high-dose intravenous steroids resulted
in rapid clinical improvement.
Finally, vancomycin as a cause of AGEP is exceptionally rare. To the best of our knowledge, there have only
been three previously reported cases of vancomycininduced AGEP in the literature [8, 9, 12]. One case included another confounding antibiotic that is more commonly implicated in AGEP, and thus, the causation
relationship was equivocal. The second case presented
typically with resolution of AGEP following cessation of
vancomycin, with no additional required interventions
such as steroids. And the third case presented atypically
with a severe AGEP course similar to our case and required systemic steroids. In the latter case, the patient
required only several days of systemic steroids with
complete clinical recovery. However, because of the presence of vancomycin-impregnated intracranial mesh in our
patient with unclear clinical significance, a prolonged systemic steroid taper was chosen for our patient.
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Conclusion
AGEP is a rare disorder characterized by acute onset of
characteristic skin eruptions, often triggered by certain
medications. This condition is typically self-limiting in
nature and tends to resolve spontaneously with cessation
of the offending agent. The use of steroids is not routinely required. However, as this case illustrates, AGEP
could present atypically with aggressive multi-organ involvement and hemodynamic compromise mimicking
septic shock despite cessation of the offending agent. In
such cases, early systemic steroid administration appears
to provide immediate hemodynamic stabilization and
clinical improvement.
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